Casi Pharmaceuticals Inc (NQ: CASI )
2.047 +0.057 (+2.89%) Streaming Delayed Price Updated: 12:36 PM EDT, Mar 29, 2023 Add to My Watchlist
All News about Casi Pharmaceuticals Inc
Fosun Pharma acquired China rights to a novel broad cancer immunotherapy candidate from VerImmune of Baltimore in an $125 million agreement. Fosun will pay VerImmune up to $125 million in upfront and...
Via Talk Markets
61 Stocks Moving In Thursday's Mid-Day Session
May 26, 2022
The Daily Biotech Pulse: Genfit Spikes On Liver Disease Drug Licensing Deal, Lyell Gets Nod For Solid Tumor Study, Decision-Day For Intra-Cellular, Argenx
December 17, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Merck Announces Publication Of Positive Data From Late-Stage Study Of Oral...
BioInvent and CASI Pharmaceuticals Announce CTA Approval for Clinical Studies of BI-1206 in NHL in China
December 10, 2021
LUND, SE / ACCESSWIRE / December 10, 2021 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV) , a biotech company focused on the discovery and development of novel and first-in-class...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following